Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Entasis Therapeutics (ETTX) stocks in Canada
Learn how to easily invest in Entasis Therapeutics stocks.
Entasis Therapeutics is a biotechnology business based in the US. Entasis Therapeutics stocks (ETTX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.75 – a decrease of 9.38% over the previous week. Entasis Therapeutics employs 47 staff and has a market cap (total outstanding stock value) of $91.5 million.
How to buy shares in Entasis Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ETTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in Entasis Therapeutics?
- Has coronavirus impacted Entasis Therapeutics shares?
- Entasis Therapeutics shares summary
- Compare share dealing platforms
- Is Entasis Therapeutics stock a buy or sell?
- Entasis Therapeutics performance over time
- Entasis Therapeutics's financials
- How volatile are Entasis Therapeutics shares?
- Does Entasis Therapeutics pay a dividend?
- Other common questions
Entasis Therapeutics stock price (NASDAQ:ETTX)Use our graph to track the performance of ETTX stocks over time.
Entasis Therapeutics shares at a glance
|Latest market close||$1.74|
|52-week range||$1.76 - $3.88|
|50-day moving average||$2.41|
|200-day moving average||$2.54|
|Wall St. target price||$7.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.14|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Entasis Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Entasis Therapeutics price performance over time
|1 week (2022-01-14)||-9.38%|
|1 month (2021-12-23)||-25.32%|
|3 months (2021-10-22)||-34.09%|
|6 months (2021-07-23)||-30.40%|
|1 year (2021-01-22)||-49.86%|
|2 years (2020-01-24)||-64.20%|
|3 years (2019-01-24)||5.34|
|5 years (2017-01-20)||N/A|
Entasis Therapeutics financials
|Gross profit TTM||$7 million|
|Return on assets TTM||-54.17%|
|Return on equity TTM||-88.57%|
|Market capitalisation||$91.5 million|
TTM: trailing 12 months
Entasis Therapeutics share dividends
We're not expecting Entasis Therapeutics to pay a dividend over the next 12 months.
Entasis Therapeutics share price volatility
Over the last 12 months, Entasis Therapeutics's shares have ranged in value from as little as $1.76 up to $3.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Entasis Therapeutics's is 1.5565. This would suggest that Entasis Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Entasis Therapeutics overview
Entasis Therapeutics Holdings Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co. , Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin.
Stocks similar to Entasis Therapeutics
Entasis Therapeutics in the news
Earnings playbook: A complete guide to this week's reports, including the first of tech
Markets are expected to remain on edge as the Fed meets in the week ahead
Netflix quietly admits streaming competition is eating into growth
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More guides on Finder
How to buy Haemonetics Corporation stock in Canada
Steps to owning and managing HAE stock, with 24-hour and historical pricing before you buy.
Go Auto Review
Use Go Auto to shop for new or used vehicles from multiple dealerships, with no hidden fees and access to bad credit financing.
How to buy Aritzia stock in Canada
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
CI Direct Trading review
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Hifi Finance (MFT) price prediction
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Kusama (KSM) price prediction
Read our expert analysis on Kusama and how the token will perform in the future.
How to buy The Sandbox (SAND) in Canada
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
COVID testing stocks
We’ve rounded up stats on some of the most popular COVID testing stocks, along with information on how they compare and how to invest.
Shiba Inu (SHIB) price, history and performance
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
Baby Doge Coin (BABYDOGE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.